Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the current state-of-the-art treatment of cholangiocarcinoma including the current …

Background Methodological limitations of prior studies have prevented progress in the
treatment of patients with borderline resectable pancreatic adenocarcinoma. Shortcomings …

Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly
toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The …

Background Bevacizumab, a monoclonal antibody against vascular endothelial growth
factor, has shown promising preclinical and clinical activity against metastatic colorectal …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib …

Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but
almost always develop resistance within several months of initiating therapy,. The …

Background Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the
epidermal growth factor receptor, is approved for use in colorectal cancer and squamous …

PURPOSE: Gemcitabine is generally considered to constitute first-line therapy for pancreatic
cancer. To determine whether the addition of fluorouracil (5-FU) improves on the results from …

Purpose: In North America, no effective therapy has been available for patients with
progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus …